[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201691884A1 - Получение загруженных пептидом микросфер на основе plga с характеристиками контролированного высвобождения - Google Patents

Получение загруженных пептидом микросфер на основе plga с характеристиками контролированного высвобождения

Info

Publication number
EA201691884A1
EA201691884A1 EA201691884A EA201691884A EA201691884A1 EA 201691884 A1 EA201691884 A1 EA 201691884A1 EA 201691884 A EA201691884 A EA 201691884A EA 201691884 A EA201691884 A EA 201691884A EA 201691884 A1 EA201691884 A1 EA 201691884A1
Authority
EA
Eurasian Patent Office
Prior art keywords
plga
obtaining
controlled delivery
loaded peptide
microsphere based
Prior art date
Application number
EA201691884A
Other languages
English (en)
Other versions
EA032580B1 (ru
Inventor
Евангелос Каравас
Эфтимиос Кутрис
Катерина Миниоти
Сотириа Хайтиду
Йоргия Папаниколау
Теофанис Мантурлиас
Original Assignee
Фарматен С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарматен С.А. filed Critical Фарматен С.А.
Publication of EA201691884A1 publication Critical patent/EA201691884A1/ru
Publication of EA032580B1 publication Critical patent/EA032580B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Новый способ получения длительно действующей инъекционной композиции на основе микросфер из биоразлагаемого сополимера D,L-лактида и гликолида, содержащих пептиды в качестве активных фармацевтических ингредиентов.
EA201691884A 2014-03-31 2014-03-31 Способ получения загруженных октреотид ацетатом микросфер на основе plga с характеристиками контролированного высвобождения EA032580B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/000858 WO2015149820A1 (en) 2014-03-31 2014-03-31 Preparation of peptide loaded plga microspheres with controlled release characteristics

Publications (2)

Publication Number Publication Date
EA201691884A1 true EA201691884A1 (ru) 2017-02-28
EA032580B1 EA032580B1 (ru) 2019-06-28

Family

ID=50486884

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691884A EA032580B1 (ru) 2014-03-31 2014-03-31 Способ получения загруженных октреотид ацетатом микросфер на основе plga с характеристиками контролированного высвобождения

Country Status (22)

Country Link
US (1) US9943483B2 (ru)
EP (1) EP3125871B1 (ru)
JP (1) JP6494657B2 (ru)
KR (1) KR102218655B1 (ru)
CN (2) CN106170284A (ru)
AU (1) AU2014389015B2 (ru)
BR (1) BR112016022550B1 (ru)
CA (1) CA2944561C (ru)
CY (1) CY1124037T1 (ru)
DK (1) DK3125871T3 (ru)
EA (1) EA032580B1 (ru)
ES (1) ES2837044T3 (ru)
HR (1) HRP20210058T1 (ru)
HU (1) HUE052289T2 (ru)
LT (1) LT3125871T (ru)
MX (1) MX371139B (ru)
PL (1) PL3125871T3 (ru)
PT (1) PT3125871T (ru)
RS (1) RS61209B1 (ru)
SI (1) SI3125871T1 (ru)
WO (1) WO2015149820A1 (ru)
ZA (1) ZA201607413B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089160A1 (en) 2012-12-04 2014-06-12 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
WO2016070117A1 (en) 2014-11-02 2016-05-06 Nano Precision Medical, Inc. Implantable medical devices for extended release of therapeutic agents
KR102068578B1 (ko) * 2016-08-16 2020-01-21 중앙대학교 산학협력단 세포전달을 위한 다공성 마이크로스피어 및 이의 제조방법
AU2017375793B2 (en) * 2016-12-12 2021-03-04 Cytodigm, Inc. Microparticles and nanoparticles having negative surface charges
CN108113975B (zh) * 2018-02-02 2020-10-09 中国人民解放军军事科学院军事医学研究院 一种基于涡漩振荡器的plga微球制备方法及其应用
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
CN109106688B (zh) * 2018-08-22 2021-08-17 丽珠医药集团股份有限公司 一种醋酸奥曲肽微球的制备方法
KR102181231B1 (ko) * 2018-11-22 2020-11-20 주식회사 메디포럼제약 로티고틴 함유 고분자 미립자의 제조방법
JP2021147329A (ja) * 2020-03-16 2021-09-27 株式会社リコー 粒子の製造方法
KR20220163416A (ko) 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
CN116327735A (zh) * 2020-05-08 2023-06-27 M技术株式会社 主剂均匀分散的微球和含有其的缓释制剂
WO2021224999A1 (ja) * 2020-05-08 2021-11-11 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN116139256A (zh) * 2023-03-14 2023-05-23 复旦大学附属肿瘤医院 生长抑素/生长抑素类似物缓释膜及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
AU6510400A (en) * 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
DK1742616T3 (en) * 2004-04-30 2015-01-12 Abraxis Bioscience Llc The microsphere-discharge-system for the prolonged delivery and methods of making and using the same
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit

Also Published As

Publication number Publication date
AU2014389015B2 (en) 2019-05-09
MX371139B (es) 2020-01-20
KR20160137608A (ko) 2016-11-30
HRP20210058T1 (hr) 2021-03-05
CY1124037T1 (el) 2022-03-24
CN114191538A (zh) 2022-03-18
EP3125871A1 (en) 2017-02-08
CA2944561C (en) 2019-06-18
LT3125871T (lt) 2020-12-28
HUE052289T2 (hu) 2021-04-28
EA032580B1 (ru) 2019-06-28
DK3125871T3 (da) 2020-12-21
KR102218655B1 (ko) 2021-02-22
EP3125871B1 (en) 2020-10-21
SI3125871T1 (sl) 2021-03-31
AU2014389015A1 (en) 2016-09-29
WO2015149820A1 (en) 2015-10-08
PL3125871T3 (pl) 2021-04-19
ES2837044T3 (es) 2021-06-29
US9943483B2 (en) 2018-04-17
PT3125871T (pt) 2021-01-06
JP2017509661A (ja) 2017-04-06
JP6494657B2 (ja) 2019-04-03
BR112016022550A2 (ru) 2017-08-15
US20170281547A1 (en) 2017-10-05
ZA201607413B (en) 2018-11-28
BR112016022550B1 (pt) 2023-03-28
MX2016012846A (es) 2017-05-09
CA2944561A1 (en) 2015-10-08
RS61209B1 (sr) 2021-01-29
CN106170284A (zh) 2016-11-30

Similar Documents

Publication Publication Date Title
EA201691884A1 (ru) Получение загруженных пептидом микросфер на основе plga с характеристиками контролированного высвобождения
AR121749A2 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
EA201691448A1 (ru) Гибридосомы, содержащие их композиции, способы их получения и их применения
CO2018003558A2 (es) Método de cristalización y biodisponibilidad
CL2014003215A1 (es) Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 31 y 43 kda y una viscosidad inherente entre 0,27 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion
CL2014003216A1 (es) Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 30 y 46 kda y una viscosidad inherente entre 0,25 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion.
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
EA201201570A1 (ru) Способы приготовления инъекционных композиций пролонгированного действия
EP3673897A4 (en) INJECTABLE PHARMACEUTICAL COMPOSITION WITH MELOXICAM AND METHOD FOR MANUFACTURING IT
CL2023002345A1 (es) Composiciones y métodos para fabricar microparticulas de proteína.
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
EA201792235A1 (ru) Инъецируемые препараты замедленного высвобождения, содержащие изоксазолиновое действующее вещество, способы и применение
MX2019000381A (es) Formulacion para la administracion de arn.
SG11201805123XA (en) Pharmaceutical composition comprising anti-human tslp receptor antibody
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
BR112016016297A2 (pt) Aparelho para cortar um polímero superabsorvente, e método para preparar um polímero superabsorvente
SA517381298B1 (ar) تركيبة صيدلية بثبات محسن
EA201691741A1 (ru) Фармацевтическая композиция
AR099558A1 (es) Régimen de dosaje del compuesto fgf-18
EA201591111A1 (ru) Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида
RU2017126083A (ru) Предшественники ацетальдегида
EA201792417A1 (ru) Лиофилизированный фармацевтический состав рифабутина и способ его получения
WO2015161841A3 (de) Injizierbare und implantierbare trägersysteme auf basis von modifizierten poly(dikarbonsäure-polyol estern) zur kontrollierten wirkstofffreisetzung
MX2015010163A (es) Bionanoparticulas biodegradables para liberacion del peptido gse24-2, procedimiento de obtencion y utilizacion.
李占山 Predicting Hematology Toxicity and Choosing Starting Dose of Paclitaxel: Comparison of 3 kinds of Infusion Schedules